Allon Therapeutics Inc.
TSX : NPC

Allon Therapeutics Inc.

March 02, 2011 16:53 ET

Allon CEO to Present at Life Science Innovation Northwest and Live Online at RetailInvestorConferences.com

VANCOUVER, BRITISH COLUMBIA--(Marketwire - March 2, 2011) - Allon Therapeutics Inc. (TSX:NPC) President and CEO Gordon McCauley will present an update of the Company's business progress tomorrow at 9:35 a.m. PST / 12:35 p.m. EST at the Life Science Innovation Northwest (LSINW) in Seattle, and then at 12 p.m. PST / 3 p.m. EST live online at RetailInvestorConferences.com.

Life Science Innovation Northwest 2011 is a preeminent conference which highlights the unique innovative environment of the Pacific Northwest's life science sector and features medical technology, diagnostics, and therapeutic innovations, as well as cutting-edge scientific and educational developments in global health.

RetailInvestorConferences.com, created by BetterInvesting (NAIC) PR Newswire and MUNCmedia, is the first monthly virtual investor conference series that provides an interactive forum for presenting companies to meet directly with retail investors using a graphically-enhanced online platform.

The RetailInvestorConferences.com presentation is being webcast live at: www.retailinvestorconferences.com > red "register / watch event now" button

This will be a live, interactive online event where investors are invited to ask the company questions in real-time both in the presentation hall as well as the company's "virtual trade booth." If attendees are not able to join the event live in real-time, an on-demand archive will be available for 90 days.

It is recommended that investors pre-register to save time and receive event updates.

About Allon

Allon Therapeutics Inc. is a clinical-stage biotechnology company focused on developing the first drugs that impact the progression of neurodegenerative diseases. Allon's lead drug davunetide, is proceeding in a Phase 2/3 clinical trial in an orphan indication, progressive supranuclear palsy (PSP), under an SPA with the FDA. This pivotal trial is based upon statistically significant human efficacy demonstrated in amnestic mild cognitive impairment, cognitive impairment associated with schizophrenia, and positive biomarker data.

The Company is listed on the Toronto Stock Exchange under the trading symbol "NPC" (Neuro Protection Company™) and based in Vancouver. For additional information please visit the Company's website: www.allontherapeutics.com.

Forward Looking Statements

Statements contained herein, other than those which are strictly statements of historical fact may include forward-looking information. Such statements will typically contain words such as "believes", "may", "plans", "will", "estimate", "continue", "anticipates", "intends", "expects", and similar expressions. While forward-looking statements represent management's outlook based on assumptions that management believes are reasonable, forward-looking statements by their nature are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by them. Such factors include, among others, the inherent uncertainty involved in scientific research and drug development, Allon's early stage of development, lack of product revenues, its additional capital requirements, the risks associated with successful completion of clinical trials and the long lead-times and high costs associated with obtaining regulatory approval to market any product which Allon may eventually develop. Other risk factors include the limited protections afforded by intellectual property rights, rapid technology and product obsolescence in a highly competitive environment and Allon's dependence on collaborative partners and contract research organizations. These factors can be reviewed in Allon's public filings at www.sedar.com and should be considered carefully. Readers are cautioned not to place undue reliance on such forward-looking statements. Similarly, nothing in this press release is meant to promote a pharmaceutical product or make a regulated claim of efficacy.

Contact Information